Comparative characteristics of major international and national guidelines for the treatment of chronic hepatitis С
- Authors: Efremova O.S1, Yurin O.G1
-
Affiliations:
- Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Issue: No 3 (2016)
- Pages: 27-34
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278436
- ID: 278436
Cite item
Abstract
Antiviral therapy for chronic hepatitis C has changed significantly in recent years. A regimen using pegylated interferon alpha-2a or alpha-2b and ribavirin has long been the gold standard of treatment. However, its low efficiency necessitates a search for more effective treatments. In 2014-2015, there was a breakthrough in the treatment of chronic hepatitis C, which was marked by the entry of just several direct-acting antiviral agents into the market. The advent of new drugs has opened up a possibility to perform shorter interferon-free therapy cycles and to enhance therapy efficiency to over 95%.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
O. S Efremova
Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: ks517@yandex.ru
Moscow
O. G Yurin
Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: oleg_gerald@mail.ru
Moscow
References
- WHO. Guidelinesfor the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization, 2015.
- Simmonds P. Viral heterogeneity of the hepatitis C virus. J. Hepatology 1999; 31(Suppl 1): 54-60.
- Keeffe E.B. Management of Hepatitis C Treatment Failure. 2003. http://www.hcvadvocate.org/hcsp/articles/Keeffe-3.html
- Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treat-ment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965.
- Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gon3ales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N. Engl. J. Med. 2002; 347: 975-982.
- Hadziyannis S.J., Cheinquer H., Morgan T., Diago M., Jensen D.M., Sette H. Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efPcacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose [abstract]. J. Hepatol. 2002; 36(Suppl 1): 3.
- McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., Nyberg L.M., Lee W.M., Ghalib R.H., Schiff E.R., Galati J.S., Bacon B.R., Davis M.N., Mukhopadhyay P., Koury K., Noviello S., Pedicone L.D., Brass C.A., Albrecht J.K., Sulkowski M.S. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361(6): 580-593.
- Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowei N.H. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364(25): 2405-2416.
- Poordad F., McCone J.Jr., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S. Boceprevir for untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364(13): 1195-1206.
- Park C., Jiang S., Lawson K.A. Efficacy and safety of telapre-vir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J. Clin. Pharm. Ther. 2014; 39: 14-24.
- Perry C.M. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012; 72(5): 619-641.
- Rowen K. Zetterman. HCV Treatment: Where We’re At, Where We’re Going. Medscape 2013; 38(11-12): 1365-1372.
- Salam K.A., Akimitsu N. Hepatitis C virus NS3 inhibitors: current and future perspectives. Biomed. Res. Int. 2013; 2013:467869. Epub 2013, Oct 27.
- Dusheiko G., Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon’s long good-bye. Gut 2012; 61(12): 1647-1652.
- Wilby K.J.,. Partovi N., Ford J.A., Greanya E., Yoshida E.M. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can. J. Gastroenterol. 2012; 26(4): 205210.
- Fried M., Buti M., Dore G.J. TMC435 in combination with peginterferon and ribavirin in treatment naive HCV genotype 1 patients: final analysis of the PILLAR phase II b study. Proceedings of the 62nd Annual Meetgin of the American Assoication for the Study of Liver Diseases. San Francisco, Calif, USA. 2011.
- Chae H.B., Park S.M., Youn S.J. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. Scientific World J. 2013; 2013: 704-912.
- Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., Romero-Gomez M., Zarski J.P., Agarwal K., Buggisch P., Foster G.R., Bräu N., Buti M., Jacobson I.M., Subramanian G.M., Ding X., Mo H., Yang J.C., Pang P.S., Symonds W.T., McHutchison J.G., Muir A.J., Mangia A., Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370: 1889-1898.
- Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E., Shiffman M., Schiff E., Ghalib R., Ryan M., Rustgi V., Chojkier M., Herring R., Di Bisceglie A.M., Pockros P., Subramanian J.M., An D., Svarovskaia E., Hyland R., Pang P., Symonds W.T., McHutchison J.G., Muir A., Pound D., Fried M.W. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370: 1879-1888.
- Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Cooper C., Tam E., Marinho R.T., Tsai N., Nyberg A., Box T.D., Younes Z., Enayati P., Green S., Baruch Y., Bhandari B.R., Caruntu F.A., Sepe T., Chulanov V., Janczewska E., Rizzardini G., Gervain J., Planas R., Moreno C., Hassanein T., Xie W, King M., Podsadecki T., Reddy K.R. ABT-450/r ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 2014; 370: 1983-1992.
- Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuzem S., Agarwal K. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 2014; 370: 1973-1982.
- Lawitz E., Poordad F.F., Pang P.S., Hyland R.H., Ding X., Mo H. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-523.
- EASL. Recommendations for the treatment of hepatitis C. J. Gepatol. 2015; 2-20.
- AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Feburary 26, 2016. www.hcvguidelines.org
- Ивашкин В.Т., Ющук Н.Д., Климова Е.А., Маевская М.В., Знойко О.О., Максимов С.Л., Маев И.В, Павлов Ч.С., Малышев Н.А., Блохина Н.П., Никитин И.Г., Михайлов М.И., Кожевникова Г.М., Лобзин Ю.В., Рахманова А.Г., Жданов К.В., Чуланов В.П., Шахгильдян И.В., Богомолов П.В., Мойсюк Я.Г., Чжао А.В., Андрейцева О.И. Рекомендации по диагностике и лечению взрослых больных гепатитом С. 2014. http://arvt. ru/sites/default/files/rf-recom-gep-C-2014.pdf
- Богомолов П.О., Буеверов А.О. Эффективность и безопасность комбинированной терапии отечественными противовирусными препаратами (интераль и рибапег) хронического гепатита С. Фарматека 2006; 5: 28-32.
- Богомолов П.О., Буеверов А.О., Дубинина Н.В. Мациевич М.В., Ивашкин В.Т. Эффективность лечения больных хроническим гепатитом С с 1-м генотипом вируса стандартным интерфероном альфа. Клин. перспект. гастроэнтерол. гепатол. 2011; 21(6): 17-22.
- Ивашкин В.Т., Маевская М.В., Богомолов П.О., Никитин И.Г., Буеверов А.О., Лапшин А.В. Результаты открытого сравнительного рандомизированного исследования ОРИОН: оценка эффективности отечественных препаратов Альтевир и Фосфоглив в комбинированной терапии больных хроническим гепатитом С. Рос. журн. гастроэнтерол., гепатол, колопроктол. 2012; 22(6): 27-37.
- Маев И.В., Казюлин А.Н., Кучерявый Ю.А., Маевская Е.А. Заболевания печени (обзор материалов Семнадцатой Российской гастроэнтерологической недели, 10-12 октября 2011 г., Москва). Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012; 22(3): 49-56.
- Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., Nolt K., Nelson K.E., Strathdee S.A., Johnson L., Laeyendecker O., Boitnott J., Wilson L.E., Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
- Goedert J.J., Eyster M.E., Lederman M.M., Mandalaki T., De Moerloose P., White G.C. 2nd, Angiolillo A.L., Luban N.L., Sherman K.E., Manco-Johnson M., Preiss L., Leissinger C., Kessler C.M., Cohen A.R., DiMichele D., Hilgartner M.W., Aledort L.M., Kroner B.L., Rosenberg P.S., Hatzakis A. Endstage liver disease in persons with hemophilia and transfusion associated infections. Blood 2002; 100: 1584-1589.
- Thomas D.L., Shih J.W., Alter H.J., Vlahov D., Cohn S., Hoover D.R., Cheung L., Nelson K.E. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J. Infect. Dis. 1996; 174: 690-695.
- Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez- Garcia J., Lazzarin A. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 2004; 351: 438-450.
- Hadziyannis S.J., Sette H. Jr., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H. Jr, Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-355.
- Sulkowski M.S., Naggie S., Lalezari J., Fessel W.J., Mounzer K., Shuhart M. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-361.
- Sulkowski M.S., Sherman K.E., Dieterich D.T., Bsharat M., Mahnke L., Rockstroh J.K. Combination therapy with tela-previr for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann. Intern. Med. 2013; 159: 86-96.
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова Е.В., Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова У.А., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина В.Н. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2015; 6(приложение). 72 с.
Supplementary files
![](/img/style/loading.gif)